Skip to main content

The Globe and Mail

Cangene wins Health Canada OK for hepatitis B drug

Cangene Corp. has received conditional Health Canada approval of its HepaGam B product to fight hepatitis B after liver transplants.

Cangene said Monday the notice of compliance covers prevention of hepatitis B recurrence following liver transplantation in adults with low levels of virus replication, and requires the company to continue a confirmatory clinical study.

HepaGam B, an immune globulin injection, is the only intravenous product licensed in Canada for this treatment.

Story continues below advertisement

Hepatitis B, which damages the liver, can recur after a liver transplant as a result of infection of the liver graft by virus that remained in circulation in the body.

"There are currently no other products licensed in Canada to prevent hepatitis B recurrence following liver transplantation and we are pleased to be able to answer the unmet medical need faced by these patients," stated Cangene CEO John Langstaff.

09:36ET 22-01-07

Report an error
As of December 20, 2017, we have temporarily removed commenting from our articles as we switch to a new provider. We are behind schedule, but we are still working hard to bring you a new commenting system as soon as possible. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.